Search
Ginkgo Bioworks Holdings Inc
DNAAdd to Watchlist
10.400USD
+0.110+1.07%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
605.36MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.07%
5 Days
+1.46%
1 Month
+14.92%
6 Months
+19.54%
Year to Date
+25.15%
1 Year
-18.24%
Key Figures
10.310Open
11.090High
865.45KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
1.49%Turnover Ratio
10.280Prev. Close
10.150Low
4.79MTurnover
LossP/E Static
1.19P/B
0.00%Div Yield TTM
-26.26%ROA
17.58052wk High
0.97Volume Ratio
-547.03MNet Profit
58.21MShares
-5.3493EPS TTM
1.80Beta
-56.03%ROE
5.37052wk Low
9.14%Amplitude
84.09%Gross Margin
605.36MMarket Cap
2.59Reward/Risk
5.25%Risk Rate
TradingKey Stock Score of Ginkgo Bioworks Holdings Inc
Currency: USD Updated: 2026-07-02Key Insights
Ginkgo Bioworks Holdings Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 183 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Sell, with the highest price target at 10.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ginkgo Bioworks Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ginkgo Bioworks Holdings Inc Highlights
StrengthsRisks
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Fairly Valued
The company’s latest PE is -1.94, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 33.44M shares, decreasing 12.65% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 2.52M shares of this stock.
Analyst Rating
Based on
3
analysts
Sell
Current Rating
10.000
Target Price
-2.72%
Upside Space
Ginkgo Bioworks Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ginkgo Bioworks Holdings Inc Info
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Ticker SymbolDNA
CompanyGinkgo Bioworks Holdings Inc
CEOKelly (Jason)
Websitehttps://investors.ginkgobioworks.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Ginkgo Bioworks Holdings Inc (DNA)?
The current price of Ginkgo Bioworks Holdings Inc (DNA) is 10.40.
What is the symbol of Ginkgo Bioworks Holdings Inc?
The ticker symbol of Ginkgo Bioworks Holdings Inc is DNA.
What is the 52-week high of Ginkgo Bioworks Holdings Inc?
The 52-week high of Ginkgo Bioworks Holdings Inc is 17.58.
What is the 52-week low of Ginkgo Bioworks Holdings Inc?
The 52-week low of Ginkgo Bioworks Holdings Inc is 5.37.
What is the market capitalization of Ginkgo Bioworks Holdings Inc?
The market capitalization of Ginkgo Bioworks Holdings Inc is 605.36M.
Is Ginkgo Bioworks Holdings Inc (DNA) currently rated as Buy, Hold, or Sell?
According to analysts, Ginkgo Bioworks Holdings Inc (DNA) has an overall rating of Sell, with a price target of 10.00.
What is the Earnings Per Share (EPS TTM) of Ginkgo Bioworks Holdings Inc (DNA)?
The Earnings Per Share (EPS TTM) of Ginkgo Bioworks Holdings Inc (DNA) is -5.64.